Clinical trial · Interventional
A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma
Pilot Clinical Evaluation of a Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this pilot clinical trial is to see the potential application of a CAIX targeted PET. tracer in patients with clear cell renal cell carcinoma. The main question\[s\] it aims to answer are: * The biodistribution of the PET tracer * Whether RCC lesions can be identified by the PET tracer Participants will undergo 68Ga-NY104 PET/CT scan and images will be reviewed by nuclear medicine specialists.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Clear Cell Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-NY104 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PET scan
- description
- Patients will receive an intravenous injection of 68Ga-NY104
- interventionNames
- Drug: 68Ga-NY104
Primary outcomes (2)
- measure
- Biodistribution of 68Ga-NY104 in normal organs
- timeFrame
- From study completion to 2 hour after completion
- description
- Uptake measured by SUVmax and SUVmean in normal organs using a region-of-interest technique
- measure
- Tumor uptake of 68Ga-NY104
- timeFrame
- From study completion to 2 hour after completion
- description
- Uptake measured by SUVmax and SUVmean in suspected tumor lesions
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Confirmed or suspected metastatic ccRCC 2. Age ≥ 18 y 3. Written informed consent provided for participation in the trial 4. In the opinion of investigator, willing and able to comply with required study procedures. Exclusion Criteria: 1. Patients on VEGF TKI treatment \< 1 week before 68Ga-NY104 PET/CT. TKI is known to affect girentuximab binding in patients with ccRCC. If patients were on VEGF TKI treatment, such as sunitinib, sorafenib, cabozantinib, pazopanib, or lenvatinib, a washout of one week before 68Ga-NY104 PET/CT is required. 2. Pregnancy or breastfeeding. 3. Severe claustrophobia.
References
Publications (1)
- DERIVEDZhu W, Li X, Zheng G, Bai C, Ji Z, Zhang H, Xing H, Zhang Y, Huo L. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):3116-3125. doi: 10.1007/s00259-023-06248-7. Epub 2023 May 29. PMID 37246998